Medical Oncology Department, Shefaa Al-Orman Oncology Hospital, Luxor, Egypt.
Department OF clinical oncology, Faculty of medicine, Suez University, PO Box 43221, Suez, Egypt.
BMC Cancer. 2024 Oct 18;24(1):1289. doi: 10.1186/s12885-024-12955-7.
Pancreatic adenocarcinoma (PAC) is a disease of decimal prognosis, with around 50% of patients presenting with metastatic disease. Previous trials reported a high incidence of early onset pancreatic cancer (EOPAC) in Egypt, presenting about 25% of patients with PAC. The clinic-pathological features and prognosis of EOPAC needs more study.
A retrospective analysis of patients' records at Shefa Al-Orman comprehensive cancer center database. Patients with histo-pathologically confirmed diagnosis of PAC. We categorized patients according to the age at diagnosis into EOPAC (≤ 50 years) and average onset PAC (AOPAC). Data on risk factors, family history, presenting symptoms, clinic-pathological features, treatment, and prognosis were extracted. Patients with histopathologically confirmed diagnosis of pancreatic cancer diagnosed between December 2016-December 2022 were included.
The study cohort consisted of 412 patients. EOPAC represented 20.3% of patients, with no significant differences in risk factors and family history compared to AOPAC. Duration of symptoms before diagnosis is longer in EOPAC, with the majority of EOPAC presenting with localized disease (23.8%) and locally advanced tumors (28.5%) compared to AOPAC. AOPAC presented more with metastatic disease (64% vs. 45.2%, p = 0.003). EOPAC are usually submitted to more aggressive treatment including radical surgery, neoadjuvant therapy, and aggressive chemotherapy regimens in metastatic disease. Disease free survival (DFS) of EOPAC was shorter than AOPAC (11 months vs. 17 months, p = 0.889), but overall survival OS was significantly longer in EOPAC (10 months vs. 6 months, p = 0.013).
Patients with EOPAC in Egypt represent around 25% of cases. EOPAC tend to have a shorter disease free survival (DFS) in patients presenting with localized disease. The overall survival (OS) is longer in EOPAC compared to AOPAC. Further studies are mandatory to identify the epidemiological and risk factors of EOPAC in Egypt.
胰腺导管腺癌（PAC）是一种预后极差的疾病，约有 50%的患者就诊时已发生转移。既往研究报道，埃及胰腺内分泌癌（EOPAC）的发病率较高，约 25%的 PAC 患者属于 EOPAC。EOPAC 的临床病理特征和预后需要更多的研究。
回顾性分析 Shefa Al-Orman 综合癌症中心数据库中患者的记录。所有患者均经组织病理学证实为 PAC。我们根据诊断时的年龄将患者分为 EOPAC（≤50 岁）和平均发病 PAC（AOPAC）。提取了风险因素、家族史、首发症状、临床病理特征、治疗和预后等方面的数据。入组标准为 2016 年 12 月至 2022 年 12 月期间经组织病理学证实为胰腺恶性肿瘤的患者。
本研究队列共纳入 412 例患者。EOPAC 占 20.3%，与 AOPAC 相比，EOPAC 患者的风险因素和家族史无明显差异。EOPAC 患者的症状持续时间较长，大多数 EOPAC 患者为局限性疾病（23.8%）和局部进展期肿瘤（28.5%），而 AOPAC 患者则更多为转移性疾病（64% vs. 45.2%，p=0.003）。EOPAC 患者在转移性疾病中接受更积极的治疗，包括根治性手术、新辅助治疗和强化化疗方案。EOPAC 的无病生存期（DFS）短于 AOPAC（11 个月 vs. 17 个月，p=0.889），但 EOPAC 的总生存期（OS）明显长于 AOPAC（10 个月 vs. 6 个月，p=0.013）。
埃及 EOPAC 患者占比约为 25%。EOPAC 患者就诊时局限性疾病的无病生存期（DFS）更短。与 AOPAC 相比，EOPAC 的总生存期（OS）更长。需要进一步研究以确定埃及 EOPAC 的流行病学和风险因素。
